Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

A lithium secondary battery including: a positive electrode which contains a positive electrode active material capable of absorbing and desorbing lithium; a negative electrode which contains a negative electrode active material capable of absorbing and desorbing lithium; and a non-aqueous electrolytic solution, wherein at least one of the positive electrode or the negative electrode contains a polymer that is a reaction product of a defined compound (A) and a defined compound (B) which is different from compound (A), and the non-aqueous electrolytic solution contains an additive (X). The additive (X) is at least one compound selected from the group consisting of: a carbonate compound having a carbon-carbon unsaturated bond, a carbonate compound having a halogen atom, an alkali metal salt, a sulfonic acid ester compound, a sulfuric acid ester compound, a nitrile compound, a dioxane compound, and a substituted aromatic hydrocarbon compound.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease

The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease